Abbott Laboratories Reports Q1 Sales and EPS Growth

Abbott Laboratories announced first-quarter 2025 results, with worldwide sales reaching $10.4 billion, marking a 6.9% increase on an organic basis. The company also reaffirmed its full-year financial guidance, citing its diversified business model.

The healthcare company reported adjusted diluted earnings per share (EPS) of $1.09, surpassing analyst expectations. The strong performance was attributed to growth across multiple key business units.

Sales in the Medical Devices segment saw an organic increase of nearly 13%, driven by a strong performance in Diabetes Care, which grew by almost 20% organically. Growth was also noted in Structural Heart and Electrophysiology.

Established Pharmaceuticals sales rose approximately 8% organically, showing balanced performance across various markets. Nutrition sales increased by nearly 7% organically, led by adult nutrition products.

Abbott also highlighted new product developments, including investments in U.S. manufacturing and R&D, the CE Mark for the Volt™ Pulsed Field Ablation System, and progress in clinical trials for its Coronary IVL System and the TriClip™ device.